Although considered a single class, fecal immunochemical tests (FITs) vary in their ability to detect advanced colorectal neoplasia (ACN) and should not be considered interchangeable, new research ...

A new study published in the Journal of American Medical Association showed that despite partial participant adherence, it ...

Stool-based testing has poor sensitivity and low negative predictive value for colorectal cancer screening in patients with cystic fibrosis.

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...

Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...

Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...

Screening with fecal immunochemical tests (FITs) lowers the risk of dying from colorectal cancer (CRC), according to a study published online July 19 in JAMA Network Open. Chyke A. Doubeni, M.D., from ...

In DID analysis, the rate of incidence was reduced by 0.34 cases per person-years in the screening group as compared with the historical FIT screening group (rate ratio [RR], 0.08 [95% CI, 0.07 to ...

The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

Colorectal cancer (CRC) remains the second leading cause of cancer-related deaths in the United States, a troubling fact when considering that CRC is largely preventable and treatable if caught early.

The FIT test analyzed in the study has patients poke a stool sample with a plastic stick and return it to a lab, which checks ...